Showing results (161-170 of 190) with videos related to
Sort By:
Pageof 19
Cancer Medicine|June 24, 2016
Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practiceDouglas E Peterson, Joyce A O'Shaughnessy, Hope S Rugo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 1997
A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignanciesA W Tolcher, J A O'Shaughnessy, R B Weiss, et al.Clinical Breast Cancer|December 31, 2005
The global breast cancer burden: variations in epidemiology and survivalGabriel N Hortobagyi, Jaime de la Garza Salazar, Kathleen Pritchard, et al.BMC Research Notes|December 6, 2013
Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signalingFrankie Ann Holmes, Virginia Espina, Lance A Liotta, et al.Breast Cancer Research and Treatment|January 5, 2000
Tamoxifen and fenretinide in women with metastatic breast cancerJ Zujewski, L Pai, L Wakefield, et al.The Lancet. Oncology|February 11, 2024
Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trialCarlo Palmieri, Hannah Linden, Stephen N Birrell, et al.Breast Cancer Research and Treatment|October 23, 2014
Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samplesTimothy R Wilson, Yuanyuan Xiao, Jill M Spoerke, et al.Environmental Evidence|March 5, 2026
Global evidence for the ecological effects of greening of grey infrastructure: a systematic review protocolJessica R Allen, Louise B Firth, Melanie J Bishop, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2010
Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapyHoward A Burris, Hope S Rugo, Svetislava J Vukelja, et al.Journal of the American College of Cardiology|March 18, 2008
Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF studyRobert C Bourge, William T Abraham, Philip B Adamson, et al.Pageof 19